EcoDrugPlus

Opioid Related Nociceptin Receptor 1

Ensembl ID : ENSELUG00000018241
Gene Symbol: OPRL1
3 Cross references
191 Possible Orthologues:

Oxytocin Receptor

Ensembl ID : ENSELUG00000018081
Gene Symbol: OXTR
3 Cross references
193 Possible Orthologues:

Oxytocin Receptor

Ensembl ID : ENSELUG00000002439
Gene Symbol: OXTR
3 Cross references
186 Possible Orthologues:

P21 (Rac1) Activated Kinase 4

Ensembl ID : ENSELUG00000017809
Gene Symbol: PAK4
3 Cross references
163 Possible Orthologues:

Parathyroid Hormone 1 Receptor

Ensembl ID : ENSELUG00000023004
Gene Symbol: PTH1R
3 Cross references
198 Possible Orthologues:

Peroxisome Proliferator Activated Receptor Alpha

Ensembl ID : ENSELUG00000007870
Gene Symbol: PPARA
3 Cross references
384 Possible Orthologues:

Peroxisome Proliferator Activated Receptor Delta

Ensembl ID : ENSELUG00000006945
Gene Symbol: PPARD
3 Cross references
352 Possible Orthologues:

Peroxisome Proliferator Activated Receptor Delta

Ensembl ID : ENSELUG00000011315
Gene Symbol: PPARD
3 Cross references
392 Possible Orthologues:

Peroxisome Proliferator Activated Receptor Gamma

Ensembl ID : ENSELUG00000013192
Gene Symbol: PPARG
4 Cross references
390 Possible Orthologues:

Peroxisome Proliferator-Activated Receptor Alpha

Ensembl ID : ENSELUG00000007872
Gene Symbol: LOC105018462
3 Cross references
397 Possible Orthologues:

Phosphatidylinositol 3-Kinase Regulatory Subunit Gamma

Ensembl ID : ENSELUG00000020939
Gene Symbol: LOC105024545
2 Cross references
188 Possible Orthologues:

Phosphatidylinositol 3-Kinase Regulatory Subunit Gamma-Like

Ensembl ID : ENSELUG00000001241
Gene Symbol: LOC109614581
3 Cross references
190 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).